Market Research Reports, Inc. has announced the addition of “Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments” research report to their offering. See more at- http://mrr.cm/oXg

1. www.MarketResearchReports.com
Growth
Driven by Rising
Prevalence, Continued
Success of Velcade,
Revlimid and Emerging
Supplementary
Treatments
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: October 1, 2015
 Number of Pages: 117
 Geography Coverage: Asia Pacific
 Available Format: PDF
Price For Single User License: USD 4,995
Price For Site User License: USD 9,990
Price For Global User License: USD 14,985
Delivery Time: Within 24 Hours (During Working Days)

3. www.MarketResearchReports.com
About the Report
Multiple Myeloma Therapeutics in Asia-Pacific Markets to
2021 - Growth Driven by Rising Prevalence, Continued
Success of Velcade, Revlimid and Emerging
Supplementary Treatments report provides analysis of the
multiple myeloma therapeutics space across the Asia-
Pacific (APAC) countries of India, China, Australia and
Japan, with annualized market data from 2014 and
forecast to 2021.
Key topics covered include treatment usage patterns,
annual therapy costs, and market growth projections for
multiple myeloma treatment in the APAC region.

4. www.MarketResearchReports.com
Key Highlights:
The treatment market for multiple myeloma across the
Asia-Pacific (APAC) countries of China, India, Japan, and
Australia will rise in value from $1.7 billion in 2014 to $2.8
billion by 2021, representing a Compound Annual Growth
Rate (CAGR) of 7.4%, according to new report.
Multiple Myeloma (MM) is a hematological malignancy
characterized by the proliferation of plasma cells in the
bone marrow. The disease is incurable; although over the
past decade there have been significant improvements in
therapy, driven by a greater understanding of
pathophysiology.
MM represents about 0.8–1% of all cancer cases
worldwide and approximately 10% of all hematological
cancers, with incidence rates ranging from 0.4 to 5 per
100,000 persons in different parts of the world.

5. www.MarketResearchReports.com
Key Highlights Continues…
Without any treatment, the median survival of a
myeloma patient is about six months, but this can be
extended with the use of various forms of treatment.
There are now five classes of drugs used in the treatment
of myeloma: immunomodulatory drugs, chemotherapy,
proteasome drugs, Histone Deacetylase (HDAC) inhibitors
and steroids.
Many of the notable drugs in these classes were
approved over the past 10–15 years. Treatment using
these novel drugs and high-dose chemotherapy with
hematopoietic Stem-Cell Transplant (SCT) has been shown
to improve median survival to five years, which makes
this the current standard therapy.
However, many patients suffer relapse or develop
treatment resistance, leaving a need to develop safe and
effective treatments that prolong the duration of
remission and improve survival.

6. www.MarketResearchReports.com
Reasons to Buy:
Understand the clinical context of MM by considering
symptoms, etiology, pathophysiology, epidemiology,
diagnosis, and treatment options.
Identify the therapeutic strategies, products, and
companies that dominate the current marketed products
landscape and recognize gaps and areas of unmet need.
Appreciate key pipeline trends in molecule type,
administration route, mechanism of action, and novelty.
Consider market opportunities and potential risks by
examining trends in clinical trial size, duration, and failure
rate by stage of development, molecule type, and
mechanism of action.

7. www.MarketResearchReports.com
Reasons to Buy Continues…
Recognize the late-stage pipeline molecules that have
demonstrated strong therapeutic potential by examining
clinical trial data and multi-scenario product forecast
projections.
Compare treatment usage patterns, annual therapy
costs, and market growth projections for India, China,
Australia and Japan.
Discover trends in licensing and co-development deals
concerning MM products and identify the major strategic
consolidations that have shaped the commercial
landscape.

8. www.MarketResearchReports.com
Report Coverage:
1. Introduction
2. Marketed Products
3. Pipeline Products
4. Market Forecast to 2021
5. Drivers and Barriers for the Disease Market
6. Deals and Strategic Consolidations
7. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

9. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter
at:
http://www.marketresearchreports.com/subscribe-to-
newsletter

10. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/oXg
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)